Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

BACKGROUND: Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JI...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoels, Monika M, van der Heijde, Désirée, Breedveld, Ferdinand C, Burmester, Gerd R, Dougados, Maxime, Emery, Paul, Ferraccioli, Gianfranco, Gabay, Cem, Gibofsky, Allan, Gomez-Reino, Juan Jesus, Jones, Graeme, Kvien, Tore K, Murikama, Miho M, Nishimoto, Norihiro, Smolen, Josef S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595140/
https://www.ncbi.nlm.nih.gov/pubmed/23144446
http://dx.doi.org/10.1136/annrheumdis-2012-202470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595140/
https://www.ncbi.nlm.nih.gov/pubmed/23144446
http://dx.doi.org/10.1136/annrheumdis-2012-202470

Ejemplares similares